Aclarion

Aclarion has attracted the most respected spine surgeons in the industry to be part of our KOL program. Find out why these #thoughtleaders are using and supporting the Nociscan solution and how unique disc biomarker data helps them individualize treatment for each chronic low back pain patient in the latest episode of MedTech Gurus with Thomas Hickey. Listen now ▶️ https://lnkd.in/e_bcJrmp Christopher Ames MD Sigurd Berven Juan Uribe, MD John Keller Eric Potts Roger Härtl Gregory Basil, MD Dean Karahalios #lowbackpain #AI #ACON #ACONW #nasdaq #medtechguru

“Everyone experiences pain differently,” stated Brent Ness in a recent interview with MedTech Gurus podcast host Thomas Hickey. At Aclarion, this is why we created the Nociscan solution - to provide physicians with the unique disc biomarker data of each chronic low pain back patient to individualize treatment decisions.    Great interview about Nociscan and the key accomplishments that are driving Aclarion’s success. Listen today! https://lnkd.in/e_bcJrmp #ACON #ACONW #nasdaq #chroniclowbackpain #medtechguru

Congrats Nicholas Theodore, MD, FACS, FAANS on this incredible achievement!

In a presentation at this year’s ISSLS InternationalSociety meeting in Milan, Italy, the researchers from the Reach Center at University of California, San Francisco presented data where Nociscan AI was utilized to better understand Modic changes in patients suffering from chronic low back pain (cLBP). This research is foundational in helping physicians better understand the disc environment and create personalized and effective care plans for patients. Learn more here. https://lnkd.in/gQytzF38 #ACON #ACONW #nasdaq #spinesurgery #ISSLS2024

Let’s meet in Chicago! Attending NASS this week? Reach out at info@aclarion.com to meet with the Aclarion team to learn more about how the Nociscan solution is helping physicians around the world distinguish between painful and nonpainful lumbar discs to optimize the treatment for chronic low back pain. #NASS2024 #ACON #ACONW #nasdaq #NASS24 #lowbackpain #spinesurgery

Evidence. Growth. Access. The Aclarion team is focused on delivering key milestones to drive the expansion of the Nociscan solution to chronic low back pain (cLBP) patients across the world. To date in 2024, we have already met many of our commercial goals toward our company mission of leading with clinical evidence to improve the care of cLBP. And the year isn't done yet…. Read the full company update here. https://lnkd.in/gKqYGsge #ACON #ACONW #nasdaq #spinesurgery #lowbackpain

We are excited to announce the completion of the first Nociscan exams for patients enrolled in the LIFEHAB Trial in Norway. LIFEHAB joins the NIH and ACTIVE trials in selecting Nociscan as a technology to help determine which discs to treat and the technology’s role in selecting optimal treatment options. Learn more https://lnkd.in/gkPgFZue #ACON #ACONW #nasdaq #spinesurgery #lowbackpain “We are excited to see the LIFEHAB Trial progressing on schedule and look forward to the results of the study and to the role we expect Nociscan data to play in not only helping physicians determine which discs to treat but in potentially helping to predict which treatment option is optimal for a particular patient,” Brent Ness “Although we talk frequently about driving Nociscan to standard of care for clinical use, the research market is proving to be an early adopter of our technology.”

We are excited to announce the completion of the first Nociscan exams for patients enrolled in the LIFEHAB Trial in Norway. LIFEHAB joins the NIH and ACTIVE trials in selecting Nociscan as a technology to help determine which discs to treat and the technology’s role in selecting optimal treatment options. Learn more https://lnkd.in/gkPgFZue #ACON #ACONW #nasdaq #spinesurgery #lowbackpain “We are excited to see the LIFEHAB Trial progressing on schedule and look forward to the results of the study and to the role we expect Nociscan data to play in not only helping physicians determine which discs to treat but in potentially helping to predict which treatment option is optimal for a particular patient,” Brent Ness “Although we talk frequently about driving Nociscan to standard of care for clinical use, the research market is proving to be an early adopter of our technology.”

 As we focus on expanding access to the Nociscan solution, we are excited to announce our new partnership with Justin Kubeck, MD, FAAOS, MBA and Ocean Pain and Spine to deliver Nociscan to patients in the personal injury and workers compensation market in Toms River, NJ. Learn more about this partnership here. https://lnkd.in/gvCaKEki #ACON #ACONW #nasdaq #lowbackpain #spinesurgery

The CLUE trial is growing! We are thrilled to announce the launch of the second Clinical Utility and Economic (CLUE) site at Ocean Pain and Spine in Toms River, NJ with Justin Kubeck, MD, FAAOS, MBA. This expansion allows us to build a growing body of data supporting the real-world value of adding Nociscan’s AI generated data to existing diagnostic evaluation methods for the treatment of chronic low back pain. Learn more. https://lnkd.in/gYFYzXzm   “I always tell new patients that we need to see what makes sense for their individual circumstances – whether it’s medication, or therapy, or ultimately, surgery,” explained Dr. Kubeck. “There is a protocol that I follow; I don’t ever just go in and do surgery. For me, developing the best treatment plan for an individual patient is very proceduralized. Once we determine the problem, then I say, ‘Here’s what you can expect, here are your options, and here is what we will decide together.’ Nociscan will be an invaluable decision support tool when evaluating diagnosis and treatment.”    #ACON #ACONW #nasdaq #CLUEtrial #spinesurgery #lowbackpain